Delta-aminolevulinic acid dehydratase

"ALAD" redirects here. For other uses, see Alad.

ALAD
Available structures PDB Ortholog search: PDBe RCSB List of PDB id codes 1E51, 1PV8, 5HNR, 5HMS
Identifiers
Aliases	ALAD, ALADH, PBGS, aminolevulinate dehydratase, ALA dehydratase
External IDs	OMIM: 125270; MGI: 96853; HomoloGene: 16; GeneCards: ALAD; OMA:ALAD - orthologs
Gene location (Human) Chr. Chromosome 9 (human) Band 9q32 Start 113,386,312 bp End 113,401,290 bp
Gene location (Mouse) Chr. Chromosome 4 (mouse) Band 4 B3|4 33.17 cM Start 62,427,406 bp End 62,438,155 bp
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in right adrenal gland right adrenal cortex left adrenal gland left adrenal cortex C1 segment inferior olivary nucleus dorsal motor nucleus of vagus nerve parotid gland trabecular bone right lobe of liver Top expressed in fetal liver hematopoietic progenitor cell vestibular membrane of cochlear duct epithelium of lens left lobe of liver vestibular sensory epithelium human fetus corneal stroma right kidney yolk sac efferent ductule More reference expression data BioGPS More reference expression data
Gene ontology Molecular function porphobilinogen synthase activity zinc ion binding metal ion binding catalytic activity lyase activity identical protein binding proteasome core complex binding Cellular component cytosol extracellular exosome nucleus extracellular region extracellular space secretory granule lumen ficolin-1-rich granule lumen proteasome core complex Biological process cellular response to interleukin-4 response to ionizing radiation response to platinum ion response to selenium ion response to amino acid cellular response to lead ion response to hypoxia response to cadmium ion response to fatty acid response to vitamin B1 response to organic cyclic compound response to vitamin response to nutrient response to metal ion response to zinc ion response to glucocorticoid response to arsenic-containing substance protoporphyrinogen IX biosynthetic process response to oxidative stress response to organic substance response to activity tetrapyrrole biosynthetic process porphyrin-containing compound biosynthetic process response to vitamin E response to iron ion heme biosynthetic process response to lipopolysaccharide response to nutrient levels response to lead ion response to inorganic substance response to aluminum ion response to hormone response to mercury ion metabolism response to methylmercury response to ethanol response to cobalt ion protein homooligomerization response to toxic substance response to herbicide neutrophil degranulation negative regulation of proteasomal protein catabolic process Sources:Amigo / QuickGO
Orthologs Species Human Mouse Entrez 210 17025 Ensembl ENSG00000148218 ENSMUSG00000028393 UniProt P13716 P10518 RefSeq (mRNA) NM_000031 NM_001003945 NM_001317745 NM_001276446 NM_008525 RefSeq (protein) NP_000022 NP_001003945 NP_001304674 NP_001263375 NP_032551 Location (UCSC) Chr 9: 113.39 – 113.4 Mb Chr 4: 62.43 – 62.44 Mb PubMed search
Wikidata
View/Edit Human View/Edit Mouse

Aminolevulinic acid dehydratase (porphobilinogen synthase, or ALA dehydratase, or aminolevulinate dehydratase) is an enzyme (EC 4.2.1.24) that in humans is encoded by the ALAD gene. Porphobilinogen synthase (or ALA dehydratase, or aminolevulinate dehydratase) synthesizes porphobilinogen through the asymmetric condensation of two molecules of aminolevulinic acid. All natural tetrapyrroles, including hemes, chlorophylls and vitamin B₁₂, share porphobilinogen as a common precursor. Porphobilinogen synthase is the prototype morpheein.

Function

It catalyzes the following reaction, the second step of the biosynthesis of porphyrin:

2 5-Aminolevulinic acid $\rightleftharpoons$ porphobilinogen + 2 H₂O

It therefore catalyzes the condensation of 2 molecules of 5-aminolevulinate to form porphobilinogen (a precursor of heme, cytochromes and other hemoproteins). This reaction is the first common step in the biosynthesis of all biological tetrapyrroles. Zinc is essential for enzymatic activity.

Structure

The structural basis for allosteric regulation of Porphobilinogen synthase (PBGS) is modulation of a quaternary structure equilibrium between octamer and hexamer (via dimers), which is represented schematically as 6mer* ↔ 2mer* ↔ 2mer ↔ 8mer. The * represents a reorientation between two domains of each subunit that occurs in the dissociated state because it is sterically forbidden in the larger multimers.

The PBGS quaternary structure equilibrium includes an inactive hexamer (PDB id 1PV8) that does not have subunit interactions necessary for an ordered active site lid. Dissociation to the pro-hexamer dimer can be followed by a conformational change that reorients the two αβ-barrel domains to form the pro-octamer dimer. Association of pro-octamer dimer to octamer (PDB id 1E51) includes formation of subunit interfaces that support order in the active site lid.

PBGS is encoded by a single gene and each PBGS multimer is composed of multiple copies of the same protein. Each PBGS subunit consists of a ~300 residue αβ-barrel domain, which houses the enzyme's active site in its center, and a >25 residue N-terminal arm domain. Allosteric regulation of PBGS can be described in terms of the orientation of the αβ-barrel domain with respect to the N-terminal arm domain.

Each N-terminal arm has up to two interactions with other subunits in a PBGS multimer. One of these interactions helps to stabilize a "closed" conformation of the active site lid. The other interaction restricts solvent access from the other end of the αβ-barrel.

In the inactive multimeric state, the N-terminal arm domain is not involved in the lid-stabilizing interaction, and in the crystal structure of the inactive assembly, the active site lid is disordered.

Allosteric regulators

As a nearly universal enzyme with a highly conserved active site, PBGS would not be a prime target for the development of antimicrobials and/or herbicides. To the contrary, allosteric sites can be much more phylogenetically variable than active sites, thus presenting more drug development opportunities.

Phylogenetic variation in PBGS allostery leads to the framing of discussion of PBGS allosteric regulation in terms of intrinsic and extrinsic factors.

Intrinsic allosteric regulators

Magnesium

The allosteric magnesium ion lies at the highly hydrated interface of two pro-octamer dimers. It appears to be easily dissociable, and it has been shown that hexamers accumulate when magnesium is removed in vitro.

pH

Though it is not common to consider hydronium ions as allosteric regulators, in the case of PBGS, side chain protonation at locations other than the active site has been shown to affect the quaternary structure equilibrium, and thus to affect the rate of its catalyzed reaction as well.

Extrinsic allosteric regulators

Small molecule hexamer stabilization

Inspection of the PBGS 6mer* reveals a surface cavity that is not present in the 8mer. Small molecule binding to this phylogenetically variable cavity has been proposed to stabilize 6mer* of the targeted PBGS and consequently inhibit activity.

Such allosteric regulators are known as morphlocks because they lock PBGS in a specific morpheein form (6mer*).

Lead poisoning

ALAD poisoned by gray lead ions

ALAD enzymatic activity is inhibited by lead, beginning at blood lead levels that were once considered to be safe (<10 μg/dL) and continuing to correlate negatively across the range from 5 to 95 μg/dL. Inhibition of ALAD by lead leads to anemia primarily because it both inhibits heme synthesis and shortens the lifespan of circulating red blood cells, but also by stimulating the excessive production of the hormone erythropoietin, leading to inadequate maturation of red cells from their progenitors. A defect in the ALAD structural gene can cause increased sensitivity to lead poisoning and acute hepatic porphyria. Alternatively spliced transcript variants encoding different isoforms have been identified.

Deficiency

A deficiency of porphobilinogen synthase is usually acquired (rather than hereditary) and can be caused by heavy metal poisoning, especially lead poisoning, as the enzyme is very susceptible to inhibition by heavy metals.

Hereditary insufficiency of porphobilinogen synthase is called porphobilinogen synthase (or ALA dehydratase) deficiency porphyria. It is an extremely rare cause of porphyria, with less than 10 cases ever reported. All disease associated protein variants favor hexamer formation relative to the wild type human enzyme.

Heme synthesis—note that some reactions occur in the cytoplasm and some in the mitochondrion (yellow)

PBGS as the prototype morpheein

The morpheein model of allostery exemplified by PBGS adds an additional layer of understanding to potential mechanisms for regulation of protein function and complements the increased focus that the protein science community is placing on protein structure dynamics.

This model illustrates how the dynamics of phenomena such as alternate protein conformations, alternate oligomeric states, and transient protein-protein interactions can be harnessed for allosteric regulation of catalytic activity.

External links

• Human ALAD genome location and ALAD gene details page in the UCSC Genome Browser.
• delta-Aminolevulinic+Acid+Dehydratase at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
• http://www.omim.org/entry/125270?search=pbgs&highlight=pbgs

Further reading

• Bernard A, Lauwerys R (1988). "Metal-induced alterations of delta-aminolevulinic acid dehydratase". Annals of the New York Academy of Sciences. 514: 41–7. doi:10.1111/j.1749-6632.1987.tb48759.x. PMID 3327436. S2CID 41966070.
• Jaffe EK (October 2004). "The porphobilinogen synthase catalyzed reaction mechanism". Bioorganic Chemistry. 32 (5): 316–25. doi:10.1016/j.bioorg.2004.05.010. PMID 15381398.
• Roels HA, Buchet JP, Lauwerys RR, Sonnet J (August 1975). "Comparison of in vivo effect of inorganic lead and cadmium on glutathione reductase system and delta-aminolevulinate dehydratase in human erythrocytes". British Journal of Industrial Medicine. 32 (3): 181–92. doi:10.1136/oem.32.3.181. PMC 1008057. PMID 1156566.
• Ishida N, Fujita H, Fukuda Y, Noguchi T, Doss M, Kappas A, Sassa S (May 1992). "Cloning and expression of the defective genes from a patient with delta-aminolevulinate dehydratase porphyria". The Journal of Clinical Investigation. 89 (5): 1431–7. doi:10.1172/JCI115732. PMC 443012. PMID 1569184.
• Dawson SJ, White LA (May 1992). "Treatment of Haemophilus aphrophilus endocarditis with ciprofloxacin". The Journal of Infection. 24 (3): 317–20. doi:10.1016/S0163-4453(05)80037-4. PMID 1602151.
• Astrin KH, Kaya AH, Wetmur JG, Desnick RJ (August 1991). "RsaI polymorphism in the human delta-aminolevulinate dehydratase gene at 9q34". Nucleic Acids Research. 19 (15): 4307. doi:10.1093/nar/19.15.4307-a. PMC 328595. PMID 1678509.
• Wetmur JG, Kaya AH, Plewinska M, Desnick RJ (October 1991). "Molecular characterization of the human delta-aminolevulinate dehydratase 2 (ALAD2) allele: implications for molecular screening of individuals for genetic susceptibility to lead poisoning". American Journal of Human Genetics. 49 (4): 757–63. PMC 1683158. PMID 1716854.
• Plewinska M, Thunell S, Holmberg L, Wetmur JG, Desnick RJ (July 1991). "delta-Aminolevulinate dehydratase deficient porphyria: identification of the molecular lesions in a severely affected homozygote". American Journal of Human Genetics. 49 (1): 167–74. PMC 1683193. PMID 2063868.
• Potluri VR, Astrin KH, Wetmur JG, Bishop DF, Desnick RJ (July 1987). "Human delta-aminolevulinate dehydratase: chromosomal localization to 9q34 by in situ hybridization". Human Genetics. 76 (3): 236–9. doi:10.1007/BF00283614. PMID 3036687. S2CID 32211471.
• Gibbs PN, Jordan PM (June 1986). "Identification of lysine at the active site of human 5-aminolaevulinate dehydratase". The Biochemical Journal. 236 (2): 447–51. doi:10.1042/bj2360447. PMC 1146860. PMID 3092810.
• Wetmur JG, Bishop DF, Cantelmo C, Desnick RJ (October 1986). "Human delta-aminolevulinate dehydratase: nucleotide sequence of a full-length cDNA clone". Proceedings of the National Academy of Sciences of the United States of America. 83 (20): 7703–7. Bibcode:1986PNAS...83.7703W. doi:10.1073/pnas.83.20.7703. PMC 386789. PMID 3463993.
• Wetmur JG, Bishop DF, Ostasiewicz L, Desnick RJ (1986). "Molecular cloning of a cDNA for human delta-aminolevulinate dehydratase". Gene. 43 (1–2): 123–30. doi:10.1016/0378-1119(86)90015-6. PMID 3758678.
• Doss M, von Tiepermann R, Schneider J (1981). "Acute hepatic porphyria syndrome with porphobilinogen synthase defect". The International Journal of Biochemistry. 12 (5–6): 823–6. doi:10.1016/0020-711X(80)90170-6. PMID 7450139.
• Kaya AH, Plewinska M, Wong DM, Desnick RJ, Wetmur JG (January 1994). "Human delta-aminolevulinate dehydratase (ALAD) gene: structure and alternative splicing of the erythroid and housekeeping mRNAs". Genomics. 19 (2): 242–8. doi:10.1006/geno.1994.1054. PMID 8188255.
• Akagi R, Yasui Y, Harper P, Sassa S (September 1999). "A novel mutation of delta-aminolaevulinate dehydratase in a healthy child with 12% erythrocyte enzyme activity". British Journal of Haematology. 106 (4): 931–7. doi:10.1046/j.1365-2141.1999.01647.x. PMID 10519994. S2CID 24044521.
• Akagi R, Shimizu R, Furuyama K, Doss MO, Sassa S (March 2000). "Novel molecular defects of the delta-aminolevulinate dehydratase gene in a patient with inherited acute hepatic porphyria". Hepatology. 31 (3): 704–8. doi:10.1002/hep.510310321. PMID 10706561. S2CID 8998084.
• Kervinen J, Jaffe EK, Stauffer F, Neier R, Wlodawer A, Zdanov A (July 2001). "Mechanistic basis for suicide inactivation of porphobilinogen synthase by 4,7-dioxosebacic acid, an inhibitor that shows dramatic species selectivity". Biochemistry. 40 (28): 8227–36. CiteSeerX 10.1.1.374.9639. doi:10.1021/bi010656k. PMID 11444968.